GlassScriptPhysician profile
Antoun Saba Mitromaras
NPI 1841263274
$2,287.79
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $870 · 2021: $778 · 2022: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $523.04 | 2019-2021 | |
| Amarin Pharma, INC. | $305.70 | 2019-2022 | |
| Abbvie INC. | $285.20 | 2021 | |
| Merck Sharp & Dohme LLC | $264.02 | 2019-2021 | |
| Bausch Health US, LLC | $153.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.86 | 2020-2022 | |
| Novo Nordisk INC | $143.66 | 2019-2022 | |
| Allergan, INC. | $90.34 | 2020 | |
| Glaxosmithkline, LLC. | $64.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.37 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.57 | 2021 | |
| Ascensia Diabetes Care US INC. | $33.80 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.81 | 2022 | |
| Eisai INC. | $28.22 | 2021 | |
| Althera Pharmaceuticals LLC | $26.95 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.19 | 2021 | |
| Genentech USA, INC. | $21.16 | 2019 | |
| Shire North American Group INC | $19.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoun Mitromaras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.